MetaCap

GH Research (GHRS) vs Silence Therapeutics Plc American Depository Share (SLN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Silence Therapeutics Plc American Depository Share (SLN) has outperformed GH Research (GHRS) over the past year, gaining 213.9% versus a gain of 25.1%. Over five years, SLN leads with a -10.0% price change compared with -21.0% for GHRS. Silence Therapeutics Plc American Depository Share is the larger company by market cap ($1.23 billion vs $1.20 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

GHRS+25.08%SLN+213.95%
+227%+91%-44%
Nov 21, 20251 yearNov 20, 2026
GHRS-32.08%SLN-13.68%
+23%-36%-94%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

GHRS versus SLN key metrics
MetricGHRSSLN
Share price$17.53$19.81
Market cap$1.20B$1.23B
1-day change-5.55%0.00%
YTD return+38.03%+225.82%
1-year return+25.08%+213.95%
5-year return-21.00%-9.95%
EPS (TTM)$-0.94$-1.05
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$559.00K
Revenue growth (YoY)—-98.71%
Net income (latest FY)$-48.26M$-88.61M
Gross margin—61.54%
Operating margin—-16292.84%
Net margin—-15851.88%
52-week high$31.44$19.87
52-week low$12.04$4.19
Distance from 52-week high-44.24%-0.28%
Analyst consensusstrong_buyhold
Avg. price target upside+144.67%-0.30%
Average volume294.69K2.41M
Shares outstanding68.68M62.20M
Employees7388
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • SLN has outperformed GHRS by 188.9 percentage points over the past year.

About GH Research

GHRS stock →

GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression.

Health Care · Biotechnology: Pharmaceutical Preparations · 73 employees

About Silence Therapeutics Plc American Depository Share

SLN stock →

Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 88 employees

GHRS vs SLN FAQ

Which is bigger, GH Research or Silence Therapeutics Plc American Depository Share?

Silence Therapeutics Plc American Depository Share (SLN) is larger, with a market capitalization of $1.23B compared with $1.20B for GH Research (GHRS).

Which stock has performed better over the past year, GHRS or SLN?

SLN returned +213.95% over the past 12 months, compared with +25.08% for GHRS (price return, excluding dividends). Past performance does not predict future results.

Are GH Research and Silence Therapeutics Plc American Depository Share in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons